Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
JOURNAL OF HEPATOLOGY, cilt.66, sa.1, ss.11-18, 2017 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 66 Sayı: 1
- Basım Tarihi: 2017
- Doi Numarası: 10.1016/j.jhep.2016.08.008
- Dergi Adı: JOURNAL OF HEPATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.11-18
- Anahtar Kelimeler: Tenofovir disoproxil fumarate, Emtricitabine, Lamivudine resistant, Viral suppression, Bone mineral density, Renal function, LONG-TERM EFFICACY, VIRUS INFECTION, COMBINATION THERAPY, ADEFOVIR, ENTECAVIR, SAFETY, MONOTHERAPY, CIRRHOSIS, LEVEL, RISK
- Bursa Uludağ Üniversitesi Adresli: Evet
Özet
Background & Aims: Long-term treatment with tenofovir disoproxil fumarate (TDF) alone, or in combination with emtricitabine (FTC) is associated with sustained viral suppression in patients with lamivudine resistant (LAM-R) chronic hepatitis B (CHB).